Cantor Fitzgerald holds Mereo BioPharma at $7.00 target

Published 17/03/2025, 12:36
Cantor Fitzgerald holds Mereo BioPharma at $7.00 target

On Monday, Mereo BioPharma Group (NASDAQ:MREO), currently trading at $2.62, maintained its Overweight rating and $7.00 price target from Cantor Fitzgerald. The firm’s analysts focused on the potential of the company’s drug, highlighting its effectiveness in preventing fractures that would normally occur from falls or accidents. According to InvestingPro data, analyst targets range from $6.38 to $10.64, suggesting significant upside potential. The management of Mereo BioPharma also expressed confidence in the drug’s ongoing trial, known as IA2, and its prospects for success.

The analysts noted that even if the IA2 trial does not achieve its primary endpoint, the drug could still be considered clinically meaningful. For this to happen, the final analysis would need to show a 30-35% reduction in fractures. This percentage is regarded as significant by healthcare professionals. Additionally, the drug would need to demonstrate benefits on Patient-Reported Outcomes (PROs) and other measures. The company’s strong financial position, with a current ratio of 6.1 and more cash than debt on its balance sheet, provides runway for these clinical developments.

Mereo BioPharma’s management has reiterated their belief in the drug’s potential, emphasizing that patients are less likely to experience fractures with its use. This expectation is based on the observed performance of the drug in clinical settings, where patients have avoided expected fractures following accidents.

The company’s confidence is also supported by the anticipated outcomes for the IA2 trial. Success in the trial is seen as a strong possibility, and even if the primary endpoint is not met, the management believes that the drug’s overall impact on fracture reduction and other health benefits will still be significant.

In conclusion, Cantor Fitzgerald’s analysts have reaffirmed their positive stance on Mereo BioPharma’s stock, backed by the company’s promising drug developments and the management’s optimistic outlook for the ongoing IA2 trial. The $7.00 price target stands as an affirmation of the drug’s perceived value and its potential to meet clinical expectations. With the next earnings report due on March 26, 2025, investors can access comprehensive analysis and 8 additional key insights through InvestingPro’s detailed research reports.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.